OverviewSuggest Edit

Sigilon is a biotechnology company developing functional cures for patients with chronic diseases. It develops Shielded Living Therapeutics, or SLTx, platform, which combines cell engineering with innovations in biocompatible materials and enables Sigilon's product candidates to produce a range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies, and hormones. The SLTx platform is designed to improve the management of chronic diseases by overcoming the significant limitations of cell and gene therapies and the drawbacks of the current standard of care biologic-based therapies.

TypePublic
Founded2015
HQCambridge, MA, US
Websitesigilon.com
Employee Ratings4

Latest Updates

Employees (est.) (Dec 2020)96
Revenue (FY, 2019)$14.2 M(+206%)
Share Price (Sept 2021)$5.5(-4%)
Cybersecurity ratingAMore

Key People/Management at Sigilon

Rogerio Vivaldi

Rogerio Vivaldi

President, Chief Executive Officer and Director
Philip Ashton-Rickardt

Philip Ashton-Rickardt

Chief Scientific Officer
Susan Drapeau

Susan Drapeau

SVP, Head of Preclinical Development
Matthew Kowalsky

Matthew Kowalsky

Chief Legal Officer
Melodie Henderson

Melodie Henderson

VP, Intellectual Property Counsel
Olivia G. Kelly

Olivia G. Kelly

VP, Head of Diabetes Research
Show more

Sigilon Office Locations

Sigilon has an office in Cambridge
Cambridge, MA, US (HQ)
100 Binney St #600
Show all (1)

Sigilon Financials and Metrics

Sigilon Revenue

Sigilon's revenue was reported to be $14.16 m in FY, 2019 which is a 205.3% increase from the previous period.
USD

Revenue (FY, 2019)

14.2m

Revenue growth (FY, 2018 - FY, 2019), %

205.3%

Net income (FY, 2019)

(43.9m)

EBIT (FY, 2019)

(44.1m)

Market capitalization (21-Sept-2021)

172.2m

Closing stock price (21-Sept-2021)

5.5

Cash (30-Sept-2020)

62.6m

EV

138.4m
Sigilon's current market capitalization is $172.2 m.
USDFY, 2018FY, 2019

Revenue

4.6m14.2m

Revenue growth, %

205%

General and administrative expense

6.7m10.2m

R&D expense

21.0m48.1m
Annual
USDFY, 2018FY, 2019

Cash

64.1m76.1m

Accounts Receivable

136.0k

Current Assets

64.5m76.9m

PP&E

2.6m2.9m
Quarterly
USDQ3, 2020

Cash

62.6m

Accounts Receivable

67.0k

Current Assets

63.7m

PP&E

2.8m
Annual
USDFY, 2018FY, 2019

Net Income

(22.8m)(43.9m)

Depreciation and Amortization

374.0k675.0k

Accounts Payable

844.0k164.0k

Cash From Operating Activities

38.3m(50.1m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(29.2m)(39.4m)

Depreciation and Amortization

487.0k628.0k

Accounts Payable

1.7m(1.3m)

Cash From Operating Activities

(36.6m)(44.5m)
USDFY, 2018

Revenue/Employee

110.1k

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-1.9 x
Show all financial metrics

Sigilon Operating Metrics

Q3, 2020

Lead Optimization Stage Products

2

IND-Enabling Stage Products

3

Phase I/II Trials Products

1
Show all operating metrics

Sigilon Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Sigilon Online and Social Media Presence

Embed Graph

Sigilon News and Updates

Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the Medicines and Healthcare Products Regulat…

Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the second quarter ended June 30,…

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential …

Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development

CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Ajay Rai, M.B.A., as Senior Vice …

Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that the U.S. Food and Drug Administration (FDA) has …

Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Brooke Story to its Board of Dire…
Show more

Sigilon Blogs

Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., August 7, 2020 – Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcomi…

Sigilon Therapeutics Appoints Kavita Patel, M.D., to its Board of Directors

CAMBRIDGE, Mass., June 16, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Kavita Patel, M.D., to its Board of Directors. Dr. Patel, a prac…

Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance Shielded Living Therapeutics™ to the Clinic

– Proceeds will advance first-in-human clinical trial for hemophilia A in 2020 and progression and expansion of Sigilon’s pipeline – CAMBRIDGE, Mass., March 17, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shiel…

Sigilon Therapeutics to Present at the 40th Annual Cowen & Co. Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to …

Sigilon Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan 7, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to ce…

Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders

Data to be presented next month at the American Society of Hematology Annual Meeting CAMBRIDGE, Mass. — Nov. 6, 2019 — Sigilon Therapeutics announced today that it will present data at the American Society of Hematology Annual Meeting demonstrating that its novel Shielded Living TherapeuticsTM platf…
Show more

Sigilon Frequently Asked Questions

  • When was Sigilon founded?

    Sigilon was founded in 2015.

  • Who are Sigilon key executives?

    Sigilon's key executives are Rogerio Vivaldi, Philip Ashton-Rickardt and Susan Drapeau.

  • How many employees does Sigilon have?

    Sigilon has 96 employees.

  • What is Sigilon revenue?

    Latest Sigilon annual revenue is $14.2 m.

  • What is Sigilon revenue per employee?

    Latest Sigilon revenue per employee is $147.4 k.

  • Who are Sigilon competitors?

    Competitors of Sigilon include Confo Therapeutics, XBiotech and Synlogic.

  • Where is Sigilon headquarters?

    Sigilon headquarters is located at 100 Binney St #600, Cambridge.

  • Where are Sigilon offices?

    Sigilon has an office in Cambridge.

  • How many offices does Sigilon have?

    Sigilon has 1 office.